Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Popular Men's Aromas On the planet - 2Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- 3Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- 4A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- 5Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- Man triggers smoke bomb during failed crypto robbery
- Investigating the Advantages of a Bank account: A Complete Aide
- 7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- 6 Fun Urban areas For Seniors To Travel
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- Figure out How to Protect Your Gold Venture from Unpredictability
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
